Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib

Timothy P. Hughes, Jeffrey H. Lipton, Nelson Spector, Francisco Cervantes, Ricardo Pasquini, Nelma Cristina D. Clementino, Pedro Enrique Dorlhiac Llacer, Anthony P. Schwarer, Francois-Xavier Mahon, Delphine Rea, Susan Branford, Das Purkayastha, LaTonya Collins, Tomasz Szczudlo, Brian Leber

Blood (2014) 124 (5): 729–736.

https://doi.org/10.1182/blood-2013-12-544015

Published: 2014

Journal Articles

Achievement and Maintenance Of Deeper Molecular Response By Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Residual Disease On Long-Term Imatinib: ENESTcmr 36-Month Follow-Up

Brian Leber, MD, Francisco Cervantes, MD, PhD, Nelson Spector, MD, PhD, Jeffrey H. Lipton, MD, PhD, Gabriel Etienne, MD, PHD, Ricardo Pasquini, MD, PhD, Nelma Christina Clementino, MD, Agnès Guerci-Bresler, MD, Donna Forrest, MD, FRCPC, Anthony P. Schwarer, MD, Sandip Acharya, LaTonya Collins, BSN, Tomasz Szczudlo, Timothy P. Hughes, MD, MBBS

Blood (2013) 122 (21): 94–95.

https://doi.org/10.1182/blood.V122.21.94.94

Published: 2013

Journal Articles

Switching to Nilotinib Is Associated with Continued Deeper Molecular Responses in CML-CP Patients with Minimal Residual Disease After ≥ 2 Years On Imatinib: Enestcmr 2-Year Follow-up Results

Timothy P. Hughes, MD, MBBS, Jeffrey H. Lipton, MD, PhD, Nelson Spector, MD, PhD, Brian Leber, MD, Ricardo Pasquini, MD, PhD, Nelma Clementino, MD, Anthony P. Schwarer, MD, Gabriel Etienne, MD, PhD, Agnès Guerci-Bresler, MD, Susan Branford, PhD, Das Purkayastha, LaTonya Collins, BSN, Tomasz Szczudlo, Francisco Cervantes, MD, PhD

Blood (2012) 120 (21): 694.

https://doi.org/10.1182/blood.V120.21.694.694

Published: 2012

Journal Articles

Survey of the Frontline Treatment and Management of Chronic Myeloid Leukemia (CML) in a Real-Word Setting: The 3 rd Annual Update of the Worldwide Observational Registry Collecting Longitudinal Data on Management of Chronic Myeloid Leukemia Patients (The WORLD CML Registry)

Ricardo Pasquini, MD, Jorge E. Cortes, Hagop M. Kantarjian, David Joske, MBBS, FRCPA, FRACP, Luis A Meillon, MD, Oleg Zernovak, MD, Ramsathish Sivarathinasami, LaTonya Collins, BSN, Timothy P. Hughes, MD, MBBS, Dong-Wook Kim

Blood (2011) 118 (21): 1695.

https://doi.org/10.1182/blood.V118.21.1695.1695

Published: 2011

Journal Articles

A Phase III, Randomized, Open-Label Study of 400 Mg Versus 800 Mg of Imatinib Mesylate (IM) in Patients (pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Using Molecular Endpoints: 1-Year Results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) Study

Jorge Cortes, MD, Michele Baccarani, MD, François Guilhot, MD, Brian J. Druker, MD, Susan Branford, PhD, Dong-Wook Kim, MD, PhD, Fabrizio Pane, MD, Marc Rudoltz, MD, Richard Yu, LaTonya Collins, RN, BSN, Tillmann Krahnke, PhD, Jerald P. Radich, MD, Timothy P Hughes, MD

Blood (2008) 112 (11): 335.

https://doi.org/10.1182/blood.V112.11.335.335

Published: 2008

NARROW

Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib

Achievement and Maintenance Of Deeper Molecular Response By Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Residual Disease On Long-Term Imatinib: ENESTcmr 36-Month Follow-Up

Switching to Nilotinib Is Associated with Continued Deeper Molecular Responses in CML-CP Patients with Minimal Residual Disease After ≥ 2 Years On Imatinib: Enestcmr 2-Year Follow-up Results

Survey of the Frontline Treatment and Management of Chronic Myeloid Leukemia (CML) in a Real-Word Setting: The 3 rd Annual Update of the Worldwide Observational Registry Collecting Longitudinal Data on Management of Chronic Myeloid Leukemia Patients (The WORLD CML Registry)

Email alerts

ASH Publications

American Society of Hematology

Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib

Achievement and Maintenance Of Deeper Molecular Response By Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Residual Disease On Long-Term Imatinib: ENESTcmr 36-Month Follow-Up

Switching to Nilotinib Is Associated with Continued Deeper Molecular Responses in CML-CP Patients with Minimal Residual Disease After ≥ 2 Years On Imatinib: Enestcmr 2-Year Follow-up Results

Survey of the Frontline Treatment and Management of Chronic Myeloid Leukemia (CML) in a Real-Word Setting: The 3 rd Annual Update of the Worldwide Observational Registry Collecting Longitudinal Data on Management of Chronic Myeloid Leukemia Patients (The WORLD CML Registry)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only